Jaye  Thompson net worth and biography

Jaye Thompson Biography and Net Worth

Dr. Thompson has over 30 years of experience in pharmaceutical and device product development.  She is a co-founder, clinical advisor, and former Chief Operating Officer of Proxima Clinical Research, Inc. and a founder and former President of Synergos, Inc., both of which are clinical research service providers.  Dr. Thompson previously served as Senior Vice President of Clinical and Regulatory Affairs and as a member of the board of directors of Repros Therapeutics, Inc., a reproductive health company.  She also served as Senior Vice President of Clinical Development and Regulatory Affairs of Opexa Therapeutics, Inc., a multiple sclerosis cell therapy company, and as a senior clinical and regulatory leader at other clinical stage biotech companies and at inVentiv Clinical Solutions, LLC, a clinical research service provider.  Dr. Thompson has advised several of the region’s leading life science companies on strategic and regulatory planning as well as clinical product development.  She has directed and managed statistical analysis, data management, report writing, and the conduct of clinical trials for a wide variety of indications.  Dr. Thompson has been actively involved in over 200 clinical trials for drugs, biologics, and devices, and she has been associated with numerous FDA regulatory submissions and represented sponsor companies at FDA meetings and advisory committee meetings.  Dr. Thompson was appointed to the Governor’s Texas Emerging Technology Fund Advisory Committee.  She received a BS in Applied Mathematics from Texas A&M University and an MS and a PhD in Biostatistics from the University of Texas Health Science Center in Houston.

What is Jaye Thompson's net worth?

The estimated net worth of Jaye Thompson is at least $3.42 million as of October 27th, 2023. Dr. Thompson owns 260,348 shares of Greenwich LifeSciences stock worth more than $3,415,766 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Thompson may own. Learn More about Jaye Thompson's net worth.

How old is Jaye Thompson?

Dr. Thompson is currently 58 years old. There are 4 older executives and no younger executives at Greenwich LifeSciences. The oldest executive at Greenwich LifeSciences is Dr. Frank Joseph Daugherty M.D., Chief Medical Officer & Director, who is 74 years old. Learn More on Jaye Thompson's age.

How do I contact Jaye Thompson?

The corporate mailing address for Dr. Thompson and other Greenwich LifeSciences executives is , , . Greenwich LifeSciences can also be reached via phone at 832-819-3232 and via email at [email protected]. Learn More on Jaye Thompson's contact information.

Has Jaye Thompson been buying or selling shares of Greenwich LifeSciences?

Jaye Thompson has not been actively trading shares of Greenwich LifeSciences over the course of the past ninety days. Most recently, on Friday, October 27th, Jaye Thompson bought 500 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $8.57 per share, with a total value of $4,285.00. Following the completion of the transaction, the vice president now directly owns 260,348 shares of the company's stock, valued at $2,231,182.36. Learn More on Jaye Thompson's trading history.

Who are Greenwich LifeSciences' active insiders?

Greenwich LifeSciences' insider roster includes Frank Daugherty (Insider), Kenneth Hallock (Director), David McWilliams (Director), Snehal Patel (CEO), and Jaye Thompson (VP). Learn More on Greenwich LifeSciences' active insiders.

Are insiders buying or selling shares of Greenwich LifeSciences?

During the last year, Greenwich LifeSciences insiders bought shares 21 times. They purchased a total of 53,400 shares worth more than $604,290.50. The most recent insider tranaction occured on April, 1st when CEO Snehal Patel bought 3,000 shares worth more than $57,240.00. Insiders at Greenwich LifeSciences own 52.9% of the company. Learn More about insider trades at Greenwich LifeSciences.

Information on this page was last updated on 4/1/2024.

Jaye Thompson Insider Trading History at Greenwich LifeSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/27/2023Buy500$8.57$4,285.00260,348View SEC Filing Icon  
9/26/2023Buy600$8.71$5,226.00259,848View SEC Filing Icon  
7/13/2023Buy250$9.49$2,372.50259,248View SEC Filing Icon  
4/28/2023Buy250$11.22$2,805.00258,998View SEC Filing Icon  
4/11/2023Buy1,000$11.87$11,870.00258,745View SEC Filing Icon  
3/15/2023Buy250$12.71$3,177.50257,745View SEC Filing Icon  
2/24/2023Buy250$15.39$3,847.50257,495View SEC Filing Icon  
2/3/2023Buy250$20.84$5,210.00257,245View SEC Filing Icon  
1/27/2023Buy250$19.20$4,800.00256,995View SEC Filing Icon  
1/13/2023Buy250$16.50$4,125.00256,745View SEC Filing Icon  
12/16/2022Buy250$12.94$3,235.00256,495View SEC Filing Icon  
12/2/2022Buy250$13.98$3,495.00256,245View SEC Filing Icon  
4/19/2022Buy500$16.74$8,370.00255,995View SEC Filing Icon  
1/31/2022Buy500$18.47$9,235.00View SEC Filing Icon  
1/21/2022Buy500$16.33$8,165.00View SEC Filing Icon  
1/18/2022Buy500$18.87$9,435.00View SEC Filing Icon  
1/13/2022Buy1,000$19.99$19,990.00View SEC Filing Icon  
See Full Table

Jaye Thompson Buying and Selling Activity at Greenwich LifeSciences

This chart shows Jaye Thompson's buying and selling at Greenwich LifeSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Greenwich LifeSciences Company Overview

Greenwich LifeSciences logo
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Read More

Today's Range

Now: $13.12
Low: $12.30
High: $13.29

50 Day Range

MA: $15.50
Low: $11.24
High: $20.32

2 Week Range

Now: $13.12
Low: $7.58
High: $21.44

Volume

26,292 shs

Average Volume

45,295 shs

Market Capitalization

$168.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38